Lobeline treatment reduced the c‐Myc transactivation (Figure 6F) and target gene (EPRS and LARS) or MAS protein (GOT1 and MDH1) expression, without impact on LMNA or c‐Myc levels (Figures 6G and S7B), which suppressed the viability of NB cell lines, rather than of non‐transformed cells (Figure S7C). The gene discussed is GOT1; the disease is neuroblastoma.